Press release
Rett Syndrome Pipeline Drugs Analysis Report (2024 Updates): FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | Neuren Pharma, Anavex Life Sciences, Edison Pharma, Novartis
The Rett Syndrome Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
"Rett Syndrome Pipeline Insight, 2024 [https://www.delveinsight.com/sample-request/rett-syndrome-pipeline-insight?utm_source=naver&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Rett Syndrome Market.
Some of the key takeaways from the Rett Syndrome Pipeline Report:
*
Companies across the globe are diligently working toward developing novel Rett Syndrome treatment therapies with a considerable amount of success over the years.
*
Rett Syndrome companies working in the treatment market are Prilenia Therapeutics, GEXVal, Neurogene Inc, Taysha Gene Therapies, Vyant Bio, Inc, Neuren Pharmaceuticals, Anavex Life Sciences, PTC Therapeutics, Novartis, Ultragenyx Pharmaceutical, GW Pharmaceuticals, StrideBio, AMO Pharma, Prilenia Therapeutics, Neurolixis, Biohaven Pharmaceuticals, and others, are developing therapies for the Rett Syndrome treatment
*
Emerging Rett Syndrome therapies in the different phases of clinical trials are- Pridopidine, GXV-001, NGN-401, TSHA-102, VYNT-0126, Trofinetide, ANAVEX2-73 (blarcamesine), Vatiquinone, Fingolimod, Triheptanoin, Cannabidivarin, STRX 230, AMO 04, Pridopidine, NLX 101, BHV 5000, and others are expected to have a significant impact on the Rett Syndrome market in the coming years.
*
In November 2024, Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company dedicated to developing genetic medicines for rare neurological disorders, has reported positive interim results from its ongoing Phase 1/2 open-label trial. The trial, which evaluates NGN-401 gene therapy in female pediatric patients with Rett syndrome, showed promising data in the first four participants of the low-dose cohort, demonstrating a favorable safety profile.
*
In October 2024, Unravel Biosciences, Inc. ("Unravel"), an AI-driven therapeutics company focused on developing treatments for complex diseases, has partnered with the clinical research unit of PECET at the University of Antioquia in Medellin, Colombia. Certified in Good Clinical Practices by the Colombian Health Regulatory Authority (INVIMA), PECET has been designated as the study site for Unravel's RVL-001 proof-of-concept clinical trials targeting Rett syndrome (RTT) and Pitt Hopkins syndrome (PTHS).
*
In January 2024, Anavex Life Sciences Corp. announced topline results from the Phase II/III EXCELLENCE clinical trial, a randomized, double-blind, placebo-controlled study that assessed the clinical efficacy, safety, and tolerability of 30 mg ANAVEX Registered 2-73 in 92 pediatric patients with Rett syndrome (RTT) aged 5 to 17 years.
Rett Syndrome Overview
Rett syndrome is a rare genetic neurological and developmental disorder that primarily affects girls. It leads to severe cognitive and physical impairments, often becoming apparent after a period of seemingly normal development. The disorder is caused by mutations in the MECP2 gene, which is essential for brain development.
Get a Free Sample PDF Report to know more about Rett Syndrome Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/rett-syndrome-pipeline-insight [https://www.delveinsight.com/report-store/rett-syndrome-pipeline-insight?utm_source=naver&utm_medium=pressrelease&utm_campaign=gpr]
Emerging Rett Syndrome Drugs Under Different Phases of Clinical Development Include:
*
Pridopidine: Prilenia Therapeutics
*
GXV-001: GEXVal
*
NGN-401: Neurogene Inc
*
TSHA-102: Taysha Gene Therapies
*
VYNT-0126: Vyant Bio, Inc
*
Trofinetide: Neuren Pharmaceuticals
*
ANAVEX2-73 (blarcamesine): Anavex Life Sciences
*
Vatiquinone: PTC Therapeutics
*
Fingolimod: Novartis
*
Triheptanoin: Ultragenyx Pharmaceutical
*
Cannabidivarin: GW Pharmaceuticals
*
STRX 230: StrideBio
*
AMO 04: AMO Pharma
*
Pridopidine: Prilenia Therapeutics
*
NLX 101: Neurolixis
*
BHV 5000: Biohaven Pharmaceuticals
Rett Syndrome Route of Administration
Rett Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
*
Oral
*
Parenteral
*
Intravenous
*
Subcutaneous
*
Topical
Rett Syndrome Molecule Type
Rett Syndrome Products have been categorized under various Molecule types, such as
*
Monoclonal Antibody
*
Peptides
*
Polymer
*
Small molecule
*
Gene therapy
Rett Syndrome Pipeline Therapeutics Assessment
*
Rett Syndrome Assessment by Product Type
*
Rett Syndrome By Stage and Product Type
*
Rett Syndrome Assessment by Route of Administration
*
Rett Syndrome By Stage and Route of Administration
*
Rett Syndrome Assessment by Molecule Type
*
Rett Syndrome by Stage and Molecule Type
DelveInsight's Rett Syndrome Report covers around 15+ products under different phases of clinical development like
*
Late-stage products (Phase III)
*
Mid-stage products (Phase II)
*
Early-stage product (Phase I)
*
Pre-clinical and Discovery stage candidates
*
Discontinued & Inactive candidates
*
Route of Administration
Further Rett Syndrome product details are provided in the report. Download the Rett Syndrome pipeline report to learn more about the emerging Rett Syndrome therapies [https://www.delveinsight.com/sample-request/rett-syndrome-pipeline-insight?utm_source=naver&utm_medium=pressrelease&utm_campaign=gpr]
Some of the key companies in the Rett Syndrome Therapeutics Market include:
Key companies developing therapies for Rett Syndrome are - Neuren Pharmaceuticals, Anavex Life Sciences, Edison Pharmaceuticals, Novartis, Ultragenyx Pharmaceutical, GW Pharmaceuticals, Q-State Biosciences, AveXis, AMO Pharma, Neurolixis, Biohaven Pharmaceuticals, Echo Pharmaceuticals, and others.
Rett Syndrome Pipeline Analysis:
The Rett Syndrome pipeline report provides insights into
*
The report provides detailed insights about companies that are developing therapies for the treatment of Rett Syndrome with aggregate therapies developed by each company for the same.
*
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Rett Syndrome Treatment.
*
Rett Syndrome key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
*
Rett Syndrome Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Rett Syndrome market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Rett Syndrome drugs and therapies [https://www.delveinsight.com/sample-request/rett-syndrome-pipeline-insight?utm_source=naver&utm_medium=pressrelease&utm_campaign=gpr]
Rett Syndrome Pipeline Market Drivers
*
Increasing Prevalence in Rett Syndrome, increasing investment for healthcare infrastructure are some of the important factors that are fueling the Rett Syndrome Market.
Rett Syndrome Pipeline Market Barriers
*
However, side-effects associated with the treatment of Rett Syndrome, complications involved with Rett syndrome and other factors are creating obstacles in the Rett Syndrome Market growth.
Scope of Rett Syndrome Pipeline Drug Insight
*
Coverage: Global
*
Key Rett Syndrome Companies: Prilenia Therapeutics, GEXVal, Neurogene Inc, Taysha Gene Therapies, Vyant Bio, Inc, Neuren Pharmaceuticals, Anavex Life Sciences, PTC Therapeutics, Novartis, Ultragenyx Pharmaceutical, GW Pharmaceuticals, StrideBio, AMO Pharma, Prilenia Therapeutics, Neurolixis, Biohaven Pharmaceuticals, and others
*
Key Rett Syndrome Therapies: Pridopidine, GXV-001, NGN-401, TSHA-102, VYNT-0126, Trofinetide, ANAVEX2-73 (blarcamesine), Vatiquinone, Fingolimod, Triheptanoin, Cannabidivarin, STRX 230, AMO 04, Pridopidine, NLX 101, BHV 5000, and others
*
Rett Syndrome Therapeutic Assessment: Rett Syndrome current marketed and Rett Syndrome emerging therapies
*
Rett Syndrome Market Dynamics: Rett Syndrome market drivers and Rett Syndrome market barriers
Request for Sample PDF Report for Rett Syndrome Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/rett-syndrome-pipeline-insight?utm_source=naver&utm_medium=pressrelease&utm_campaign=gpr]
Table of Contents
1. Rett Syndrome Report Introduction
2. Rett Syndrome Executive Summary
3. Rett Syndrome Overview
4. Rett Syndrome- Analytical Perspective In-depth Commercial Assessment
5. Rett Syndrome Pipeline Therapeutics
6. Rett Syndrome Late Stage Products (Phase II/III)
7. Rett Syndrome Mid Stage Products (Phase II)
8. Rett Syndrome Early Stage Products (Phase I)
9. Rett Syndrome Preclinical Stage Products
10. Rett Syndrome Therapeutics Assessment
11. Rett Syndrome Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Rett Syndrome Key Companies
14. Rett Syndrome Key Products
15. Rett Syndrome Unmet Needs
16 . Rett Syndrome Market Drivers and Barriers
17. Rett Syndrome Future Perspectives and Conclusion
18. Rett Syndrome Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=rett-syndrome-pipeline-drugs-analysis-report-2024-updates-fda-approvals-clinical-trials-therapies-moa-roa-by-delveinsight-neuren-pharma-anavex-life-sciences-edison-pharma-novartis]
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Rett Syndrome Pipeline Drugs Analysis Report (2024 Updates): FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | Neuren Pharma, Anavex Life Sciences, Edison Pharma, Novartis here
News-ID: 3879312 • Views: …
More Releases from ABNewswire
"Faces of Psychosis" Redefines Art and Memoir with Unflinching Vision
Image: https://www.abnewswire.com/upload/2025/09/0dee09b98e12efa62723aec52dbb43c5.jpg
Shoreline, WA - Jairus Beane's Faces of Psychosis has ignited critical acclaim as a genre-defying masterpiece that fuses memoir, avant-garde photography, and mental health advocacy. Released today, the groundbreaking work, featuring 92 unaltered hallucinatory images, such as the visceral "Horror Strip" (page 95) and the abstract "Cotton Picasso" (page 92), positions Beane alongside visionaries like Yayoi Kusama and Frida Kahlo in transforming psychological turmoil into transcendent art. Galleries from…
Europe Payments Market Forecast to Reach USD 1.31 Trillion by 2030, Driven by Di …
Mordor Intelligence has published a new report on the Europe payments market, offering a comprehensive analysis of trends, growth drivers, and future projections.
Europe Payments Market Overview
The Europe payments market size stood at USD 0.64 trillion in 2025 and is projected to double to USD 1.31 trillion by 2030, reflecting a brisk 15.23% CAGR. This growth is fueled by a steady shift from cash to digital payments, rising adoption of mobile…
A Gentle New Book Welcomes Babies With the Words Every Child Deserves to Hear
There's a certain kind of quiet magic in those first moments with a new baby, the soft weight of their body, the deep stillness of their sleep, the questions that swirl in your heart. In her newest children's book, The Book God Makes for You Before You Are Born , author and educator Christie Rodgers captures that sacred tenderness and puts it into words.
Written as a gentle poem filled with…
The Lighted by Eugenie Giasson Illuminates a Story of Truth, Family, and Miracle …
In a world where lies thrive in darkness, author Eugenie Giasson delivers a luminous new novel, The Lighted , a sweeping story that reminds us that truth will always find a way to shine.
The journey begins in 1998, in a modest ceramic studio in Cape Cod. An elderly artist, Abel Smith, spends his final years creating seven extraordinary lamps-hand-sculpted figures of expectant mothers, adorned with silk, pearls, and crystals. To…
More Releases for Rett
Rett Syndrome Market 2025-2034 Business Outlook, Critical Insight and Growth
Introduction
Rett syndrome is a rare, progressive neurodevelopmental disorder that almost exclusively affects girls, with an incidence of roughly 1 in 10,000 to 15,000 live female births. The condition is caused primarily by mutations in the MECP2 gene, which plays a vital role in regulating brain development and synaptic function. Children with Rett syndrome typically develop normally for the first 6 to 18 months of life before symptoms such as motor…
Rett Syndrome Market: Increasing Awareness and Early Diagnosis and Advances in G …
06-06-2024: Maximize Market Research is a Business Consultancy Firm that has published a detailed analysis of the " Rett Syndrome Market". The report includes key business insights, demand analysis, pricing analysis, and competitive landscape. The analysis in the report provides an in-depth aspect at the current status of the Rett Syndrome Market, with forecasts outspreading to the year 2030.
Rett Syndrome Market size was valued at USD 350.1…
Rett Syndrome Market Industry Outlook, Size, Growth Factors and Forecast 2030
Rett Syndrome Market Insights Unveiled:
Embark on a riveting journey through the realms of the Rett Syndrome Market with the cutting-edge market intelligence of a distinguished global research firm. Immerse yourself in a rich tapestry of data and captivating visual representations that decode the enigmatic trends of both regional and global markets. This comprehensive report reveals the market's deepest ambitions, shedding luminous beams on the foremost competitors, their market valuation,…
"Understanding Rett Syndrome: Trends and Advances in the Rett Syndrome Market"
The Rett Syndrome Market, valued at USD 225.02 million in 2022, is anticipated to surge to USD 515.06 million by 2029, reflecting a significant Compound Annual Growth Rate (CAGR) of 10.23% from 2023 to 2029.
Overview of the Rett Syndrome Market:
Rett syndrome, a rare genetic neurological and developmental disorder primarily impacting females, hinders brain development and causes progressive loss of motor skills and language. The market report underscores technological advancements…
Europe Rett Syndrome Market Size, Share, Industry, Forecast to 2029
The Europe Rett Syndrome Market 2023 Report makes available the current and forthcoming technical and financial details of the industry. It is one of the most comprehensive and important additions to the Prudent Markets archive of market research studies. It offers detailed research and analysis of key aspects of the global Europe Rett Syndrome market. This report explores all the key factors affecting the growth of the global Europe Rett…
Rett Syndrome: A Rare Disease Market with Huge Untapped Potential
What is Rett Syndrome?
Rett Syndrome is a rare genetic neurological disorder that primarily affects girls. It is caused by a mutation in the MECP2 gene, which is located on the X chromosome. The MECP2 gene provides instructions for making a protein that is critical for the normal development of the brain.
Rett Syndrome is a rare disorder, affecting about 1 in every 10,000 to 15,000 live female births. It is a…
